CA Patent

CA2524948A1 — Novel pyridopyrazines and use thereof as kinase inhibitors

Assigned to Aeterna Zentaris GmbH · Expires 2004-12-02 · 21y expired

What this patent protects

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of general formula (I), the production and use thereof as medicaments, especially for the treatment of malignant and other diseases based on pathological cell proliferations.

USPTO Abstract

The invention relates to novel pyrido[2,3-b]pyrazine derivatives of general formula (I), the production and use thereof as medicaments, especially for the treatment of malignant and other diseases based on pathological cell proliferations.

Drugs covered by this patent

Patent Metadata

Patent number
CA2524948A1
Jurisdiction
CA
Classification
—
Expires
2004-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Aeterna Zentaris GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.